Opportunities abound in Rituxan/MabThera biosimilars market

12 February 2021
biosimilars_samples_large

The Business Research Company has released a report on the market for biosimilars referencing Roche’s (ROG: SIX) blockbuster cancer drug Rituxan/MabThera (rituximab).

North America accounted for 48% of the global market for these copycat biologics, according to the report, making it the most lucrative region, followed by Western Europe and Eastern Europe.

Looking ahead, the fastest-growing regions in the rituximab biosimilar market will be South America and Asia Pacific, where growth will be at compound annual growth rates (CAGRs) of 36.7% and 29.2%, respectively.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars